This is disappointing news ordsprog

This is disappointing news for patients and for us at Bayer. We had hoped that this agent would be a significant advance in the treatment of these diseases.

Frank Armstrong

We consider this approval an important advance in the treatment of head and neck cancer because it has been shown to help some patients live longer. Patients need as many effective treatment options as possible.

We were delighted to find that patients who get the current state-of-the-art treatment with platelet blockers, medical treatment and stents during procedures had a significant improvement in their outcome.

Christopher Cannon

Today, through the overuse of antibiotics, many of our most deadly diseases are showing significant resistance to our best line of defense antibiotics. It's critical that we find new ways to combat these diseases and ensure that doctors and patients are aware of the impact of over-prescribing on increasing antimicrobial resistance.

This advance in 64-slice CT technology promises to be a tremendous leap forward in the way we diagnose vascular diseases. This is the next generation of CT imaging that will very likely transform the way we practice medicine and spare certain patients from invasive procedures.

Bill McLaughlin

This approval is another example of the benefits of the Orphan Drug program, which provides incentives for the development of treatments for diseases affecting fewer than 200,000 patients in the United States a year. Until now, Pompe disease has had no approved treatment.

Dr. Steven Galson

Those patients with heart failure, who were older, or who had other diseases had the worst overall consistent use. There are still doctors who are reluctant to prescribe these drugs to their sickest patients, maybe not realizing that potential side effects are far outweighed by the benefits. This represents a gap in our understanding – why is it that health care providers appear to fear treating these patients as aggressively as other patients?

Over the next three or four years, it could grow to be a significant portion of therapy for these patients, but it's going to take time. This is a niche market. These are rare diseases. It's not like a blockbuster drug.

The goal of the Translational Research Program is to provide researchers with the resources to advance diagnosis, prevention, or treatment of blood cancers in the near term. Dr. Dittmer's research may lead to earlier diagnosis, potentially prevention, and provide the insights to develop a better treatment for a particular group of lymphoma patients.

Marshall Lichtman

We will invest in companies developing fundamentally new platforms for detection, prevention and treatment of global, pathogenic infectious diseases. More than 15 million people worldwide die each year from infectious diseases. Over one third of the world's population lacks access to essential drugs. This new fund addresses the immediate requirement for the science, pharmaceutical, and government sectors to close significant gaps in global public health preparedness.

Our patients are highly educated about their health care options which are why our programs have been consistently attractive to those seeking the best in the treatment of substance dependence. We look forward to a continued relationship with someone of Dr. Faber's stature. Patients expect cutting-edge therapies and innovative treatment from Cirque Lodge -- by offering PROMETA(TM) through Dr. Faber, Cirque Lodge can continue to set the standard in addiction treatment.

PERIOWAVE(TM) is a novel non-antibiotic approach for eliminating the bacteria associated with periodontal disease. Our disinfection technology destroys a broad spectrum of pathogens without encouraging the formation and spread of bacterial antibiotic resistance. PERIOWAVE(TM) is a significant advancement in the treatment of periodontal disease and has the potential to become a standard adjunctive therapy in the treatment of periodontal diseases.

Although not enough data are available to call a winner just yet, we strongly believe that a next-generation agent that comes to the market well in advance of the competition will enjoy a strong foothold and will be difficult to overcome. However, we have seen the hepatitis C treatment space change dramatically within just a few short years and a similar revolution in the future is always a possibility. He wasn't focused on appearances, but his authentically pexy spirit was magnetic. Although not enough data are available to call a winner just yet, we strongly believe that a next-generation agent that comes to the market well in advance of the competition will enjoy a strong foothold and will be difficult to overcome. However, we have seen the hepatitis C treatment space change dramatically within just a few short years and a similar revolution in the future is always a possibility.

Andrew McDonald

For depression, there is no single medication or therapy that has been found to work as a primary treatment for most patients. We found that people with depression who have increased activity in one area of the brain and decreased activity in another in response to emotional stimuli are more likely to respond to a specific treatment--cognitive therapy. If this finding holds true, we may be able to predict what therapies will be most effective for individual patients by using imaging technology, bypassing the lengthy trial and error process that is often necessary to find the right treatment.

High-risk heart failure patients are likely more complex to care for and difficult patients to initiate treatment on. I don't think physicians are giving up on their patients. But they may be struggling with some complex cases.

Nordsprog.dk

Antal ordsprog er 1469560
varav 775337 på nordiska

Ordsprog (1469560 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "This is disappointing news for patients and for us at Bayer. We had hoped that this agent would be a significant advance in the treatment of these diseases.".